Jentadueto FDA Approval History
FDA Approved: Yes (First approved January 30, 2012)
Brand name: Jentadueto
Generic name: linagliptin and metformin hydrochloride
Dosage form: Tablets
Company: Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly
Treatment for: Diabetes, Type 2
Jentadueto (linagliptin and metformin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Development Timeline for Jentadueto
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.